CRISIL Research has come out with its report on Time Technoplast. According to the research firm, the company has been given the preferred vendor status for the Asian region by chemical MNCs like BASF, Clariant, Huntsman and Dow Chemicals, which is expected to further boost international packaging revenues.
CRISIL Research has come out with its report on Time Technoplast . According to the research firm, the company has been given the preferred vendor status for the Asian region by chemical MNCs like BASF, Clariant, Huntsman and Dow Chemicals, which is expected to further boost international packaging revenues. While the utilisation rates of the China capacities are also improving, demand remains low and is a monitorable.
Time Technoplast Ltd’s (Time’s) Q2FY13 results were broadly in line with CRISIL Research’s expectations. Revenues grew by 22% y-o-y to Rs 4.3 bn driven by strong growth across all segments. EBITDA margin expanded by 123 bps y-o-y (71 bps q-o-q) to 17.1% due to higher utilisation of the international capacities. Interest cost grew by 50% y-o-y (15% q-o-q) and was higher than expected. PAT grew by 39% y-o-y mainly on account of higher EBITDA. The company’s domestic packaging business continues to do well and the capacities across Asia are also reporting good traction now. However, the orders for composite cylinders have not picked up and the same remains a monitorable. Driven by Time’s market leadership in the domestic packaging industry, we maintain the fundamental grade of 4/5, indicating that its fundamentals are superior relative to other listed securities in India.
Good traction witnessed in the international packaging business
No orders for composite cylinders in hand; other businesses doing well
Broadly maintain earnings estimates for FY13 and FY14; fair value maintained at Rs 55
Disclaimer: This report (Report) has been commissioned by the Company/Investor/Exchange and prepared by CRISIL. The report is based on data publicly available or from sources considered reliable by CRISIL (Data). However, CRISIL does not guarantee the accuracy, adequacy or completeness of the Data / Report and is not responsible for any errors or omissions or for the results obtained from the use of Data / Report. Opinions expressed herein are CRISIL's opinions as on the date of this Report. The Data / Report are subject to change without any prior notice. Nothing in this Report constitutes investment, legal, accounting or tax advice or any solicitation, whatsoever. The Report is not a recommendation to buy / sell or hold any securities of the Company. CRISIL especially states that it has no financial liability, whatsoever, to the subscribers / users of this Report. This Report is for the personal information of the authorized recipient only. This Report should not be reproduced or redistributed or communicated directly or indirectly in any form to any other person or published or copied in whole or in part especially outside India, for any purpose.
© CRISIL Limited . All Rights Reserved. Published under permission from CRISIL"
To read the full report click here
Set email alert for
ADS BY GOOGLE
video of the day
Gung-ho over pharma; see BPCL rise 30-40% more: Dimensions